Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Extra FY 2003 Funding, User Fee Program Launch A Given – Industry

This article was originally published in The Gray Sheet

Executive Summary

FDA will receive the additional $15 mil. in funding that it needs in FY 2003 to implement the just-passed device user fee legislation, the medical device industry expects

You may also be interested in...



Hancock Jaffe Eyes Mid-Year Approval Of ProCol Vascular Bioprosthesis

Hancock Jaffe will begin this spring a 180-patient randomized trial of its ProCol prosthetic hemodialysis vascular graft as a replacement for failed native arteriovenous (AV) fistulae

Hancock Jaffe Eyes Mid-Year Approval Of ProCol Vascular Bioprosthesis

Hancock Jaffe will begin this spring a 180-patient randomized trial of its ProCol prosthetic hemodialysis vascular graft as a replacement for failed native arteriovenous (AV) fistulae

IVD National Fee Schedule, MDUFMA Oversight Among AdvaMed 2003 Goals

Securing adequate Medicare payment for in vitro diagnostics is one of several legislative priorities for AdvaMed in 2003

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel